Relationship between the intensity of heparin anticoagulation and clinical outcomes in patients receiving glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction

Catheterization and Cardiovascular Interventions

Volumn 81, Issue 1, 2013, Pages E9-E14

  Rozenman, Yoseph ^a   Mehran, Roxana ^b   Witzenbichler, Bernhard ^c   Dangas, George ^b   Desaga, Martin ^d   Kochman, Janusz ^e   Nilsen, Dennis W ^f   Finkelstein, Ariel ^g   Mosseri, Morris ^h   Stone, Gregg W ⁱ  

^a TEL AVIV UNIVERSITY   (Israel)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Amper Kliniken   (Germany)

^e MEDICAL UNIVERSITY OF WARSAW   (Poland)

^f STAVANGER UNIVERSITY HOSPITAL   (Norway)

^g TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^h MEIR MEDICAL CENTER   (Israel)

ⁱ Department of Medicine   (United States)

Author keywords

antiplatelets; bleeding; ischemia; unfractionated heparin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DRUG EFFECT; DRUG USE; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS;

EID: 84871718246     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24279     Document Type: Article

References (23)

1. Xiao Z, Theroux P,. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998; 97: 251-256.
2. Young E, Prins M, Levine MN, Hirsh J,. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Hemostasis 1992; 67: 639-643.
3. Horne MK III, Hutchison KJ,. Simultaneous binding of heparin and platelet factor-4 to platelets: Further insights into the mechanism of heparin-induced thrombocytopenia. Am J Hematol 1998; 58: 24-30.
4. Warkentin TE, Greinacher A,. Heparin-induced thrombocytopenia: Recognition, treatment, and prevention: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126 (3 suppl): 311S-337S.
5. Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358: 2457-2467.
6. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S,. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-782.
7. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92: 930-935.
8. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292: 1555-1562.
9. Chew DP, Bhatt DL, Lincoff AM, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: Aggregate results from 6 randomized, controlled trials. Circulation 2001; 103: 961-966.
10. Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ,. Relationship between activated clotting time and ischemic or hemorrhagic complications: Analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 2004; 110: 994-998.
11. Pinto DS, Lorenz DP, Murphy SA, et al. Association of an activated clotting time ≤250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy). Am J Cardiol 2003; 91: 976-978.
12. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-2230.
13. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
14. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203-2216.
15. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355: 1006-1017.
16. Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464-1476.
17. Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: A risk model from the ACUITY trial. Eur Heart J 2009; 30: 1457-1466.
18. Stone GW,. Ischemia versus bleeding: The art of clinical decision-making. Lancet 2009; 373: 695-696.
19. Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359: 688-696.
20. Stabile E, Nammas W, Salemme L, et al. The CIAO (coronary interventions antiplatelet-based only) study: A randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention. J Am Coll Cardiol 2008; 52: 1293-1298.
21. Rich JD, Maraganore JM, Young E, et al. Heparin resistance in acute coronary syndromes. J Thromb Thrombolysis 2007; 23: 93-100.
22. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47: e1-e121.
23. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.